Popular on EntSun
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com - 243
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 222
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures - 216
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement - 207
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV - 157
- Token-Operated Sake Service Opens at Tobu Nikko Station - 134
- Honoring Black History, Culture, and Community in Fall River - 131
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research - 125
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits - 117
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI) - 111
Similar on EntSun
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Colbert Packaging Announces WBENC Recognition
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
Australian Nuclear Science and Technology Organization (ANSTO), the new production partner of OncoBeta® GmbH in Australia
EntSun News/10890809
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
MUNICH - EntSun -- Garching n. Munich, Germany and Lucas Heights, NSW, Australia – OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies is pleased to announce that it has formalized it's manufacturing partnership with the Australian Nuclear Science and Technology Organization (ANSTO).
Following the completion of all regulatory approvals ANSTO will produce OncoBeta's novel Rhenium-SCT® therapeutic for the treatment of non-melanoma skin cancer. OncoBeta® GmbH expects to launch Rhenium-SCT® by late 2021.
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. OncoBeta's Rhenium-SCT® will offer a new and highly effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, Chief Operating Officer at OncoBeta® GmbH and CEO of OncoBeta International GmbH stated: "This is a huge step forwards for our organization. We are very excited to bring our technology to Australia and ANSTO is a key partner of ours in the goal of helping thousands of Australians afflicted with non-melanoma skin cancer."
Mar Olmeda Palomar, Medical Engineering Manager at OncoBeta® GmbH stated: "After the successful commissioning of the production line at ANSTO, we are more confident than ever in our partnership with them. It's been a pleasure to work closely with ANSTO's experienced and motivated team. We believe they are the best partner to help us bring the Rhenium-SCT® to Australia."
More on EntSun News
ANSTO General Manager Business Development and Commercialization, Rosanne Robinson stated, "ANSTO has a long-standing relationship with OncoBeta® GmbH and is excited to be their Australian manufacturing partner. Commissioning of the production line has been completed and we look forward to Australian patients having access to OncoBeta's innovative therapy for non-melanoma skin cancers. ANSTO has extensive experience in the manufacturing and delivering radiopharmaceutical diagnostics, therapies and medical devices and this project enables us to continue delivering on our core mission of improving the health of Australians and supporting industry. OncoBeta® GmbH joins our growing nandin innovation community, focussed on attracting entrepreneurs, early stage start-ups and innovative companies who want to leverage the opportunity to be co-located with ANSTO and to access our unique expertise in the nuclear industry."
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About ANSTO
ANSTO leverages great science to deliver big outcomes. We partner with a broad range of industry partners to apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment. ANSTO is the home of Australia's most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.
More on EntSun News
For more information visit www.ansto.gov.au
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at Garching near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® GmbH undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Following the completion of all regulatory approvals ANSTO will produce OncoBeta's novel Rhenium-SCT® therapeutic for the treatment of non-melanoma skin cancer. OncoBeta® GmbH expects to launch Rhenium-SCT® by late 2021.
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. OncoBeta's Rhenium-SCT® will offer a new and highly effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, Chief Operating Officer at OncoBeta® GmbH and CEO of OncoBeta International GmbH stated: "This is a huge step forwards for our organization. We are very excited to bring our technology to Australia and ANSTO is a key partner of ours in the goal of helping thousands of Australians afflicted with non-melanoma skin cancer."
Mar Olmeda Palomar, Medical Engineering Manager at OncoBeta® GmbH stated: "After the successful commissioning of the production line at ANSTO, we are more confident than ever in our partnership with them. It's been a pleasure to work closely with ANSTO's experienced and motivated team. We believe they are the best partner to help us bring the Rhenium-SCT® to Australia."
More on EntSun News
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- The Battle for the Enchanted Forest Brings Fantasy, Fun, and Fundraising!
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
ANSTO General Manager Business Development and Commercialization, Rosanne Robinson stated, "ANSTO has a long-standing relationship with OncoBeta® GmbH and is excited to be their Australian manufacturing partner. Commissioning of the production line has been completed and we look forward to Australian patients having access to OncoBeta's innovative therapy for non-melanoma skin cancers. ANSTO has extensive experience in the manufacturing and delivering radiopharmaceutical diagnostics, therapies and medical devices and this project enables us to continue delivering on our core mission of improving the health of Australians and supporting industry. OncoBeta® GmbH joins our growing nandin innovation community, focussed on attracting entrepreneurs, early stage start-ups and innovative companies who want to leverage the opportunity to be co-located with ANSTO and to access our unique expertise in the nuclear industry."
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About ANSTO
ANSTO leverages great science to deliver big outcomes. We partner with a broad range of industry partners to apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment. ANSTO is the home of Australia's most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.
More on EntSun News
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Colbert Packaging Announces WBENC Recognition
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Bay Street Yard to host "Love Island" finale watch party July 13
For more information visit www.ansto.gov.au
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at Garching near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® GmbH undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Source: OncoBeta GmbH
Filed Under: Technology
0 Comments
Latest on EntSun News
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- American Made Ivey Abitz Bespoke Clothing Travels for Summer
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- Bruce In The USA Brings Immersive Bruce Springsteen Celebration to Frederick This October
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
- Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
- Mental: Elderly Abuse a Documentary
- Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
- Rising to New Heights in the Mile High City with Destination: Scientology, Denver
- The City's Largest and Most Elegant Dinner Party Returns on September 13, 2025
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- Voting Opens Tonight for the 2025 Spin Awards Honoring Excellence in Christian Gospel Radio
- Introducing LK Blue: The Cool-Girl Denim Brand That's Redefining LA Style Launches E-Commerce
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest